The cancer therapy developer has now collected more than $240m altogether, having completed a series C round that included Roche Venture Fund.

US-based immuno-oncology therapy developer Arch Oncology closed a series C round featuring Roche Venture Fund, the corporate venturing arm of pharmaceutical firm Roche, at $105m on Tuesday. Cowen Healthcare Investments, 3×5 Partners and Eventide Asset Management co-led the round, which included Adage Capital Management, Point72 Asset Management, Avego Healthcare Capital, FMB Research, Lightchain, RiverVest Venture…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.